Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMMONIUM CHLORIDE 2.14% vs 8-HOUR BAYER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ammonium chloride is an acidifying agent. It dissociates into ammonium and chloride ions. The ammonium ion is metabolized in the liver to urea and hydrogen ions, leading to metabolic acidosis. This reduces blood p H and increases renal excretion of alkaline urine.
Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Treatment of metabolic alkalosis,Urinary acidification to enhance excretion of weak bases (e.g., amphetamines, quinidine) or to promote dissolution of calcium phosphate stones
Relief of pain, fever, and inflammation,Reduction of risk of myocardial infarction in patients with previous MI or unstable angina,Prevention of recurrent ischemic stroke or transient ischemic attack
For metabolic alkalosis: 1.5 to 3 g (approximately 280 to 560 m Eq) intravenously over 4 to 6 hours; adjust based on serum chloride and p H.
325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.
4-6 hours; prolonged in renal impairment (up to 12-15 hours).
15-20 hours (terminal elimination half-life) for salicylate at therapeutic concentrations; prolonged to 20-30 hours at high doses due to saturation of hepatic metabolism (zero-order kinetics).
Converted to urea and hydrogen ions in the liver via the urea cycle.
Hepatic hydrolysis by esterases to salicylic acid, which is primarily conjugated in the liver via glucuronidation and glycine conjugation (salicyluric acid), with minor oxidation by cytochrome P450 (CYP2C9) to gentisic acid.
Renal: >99% as ammonium ion and chloride; minimal biliary/fecal elimination.
Renal excretion of conjugated salicylate metabolites (75% as salicyluric acid, 10% as salicyl phenolic glucuronide, 5% as salicyl acyl glucuronide, 5% as gentisic acid); 10% free salicylate; approximately 10% eliminated in feces via bile.
Negligible (<1%); not significantly bound to plasma proteins.
80-90% bound to albumin; binding is concentration-dependent and saturable.
0.3-0.5 L/kg; distributes primarily in extracellular fluid; clinical meaning: low Vd reflects limited tissue penetration.
0.15-0.2 L/kg for salicylate; distributes into synovial fluid, CNS, and placental tissues; Vd increases in acidosis.
Oral: 100% (fully absorbed); IV: 100%; topical: non-systemic.
Oral: Approximately 100% for immediate-release, but extended-release may have slightly reduced absorption (relative bioavailability 85-90% compared to immediate-release).
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min: reduce dose by 50% and monitor serum electrolytes. For GFR >60 m L/min: no adjustment.
Avoid in severe renal impairment (Cr Cl <30 m L/min). Use with caution and monitor for bleeding in moderate impairment. Reduce dose or extend interval.
No specific Child-Pugh based adjustment; use caution in severe hepatic impairment due to risk of ammonia toxicity.
Avoid in severe hepatic impairment. Use with caution in moderate impairment; monitor liver function.
Neonates and children: 1-2 m Eq/kg intravenously per dose, infused over 2-4 hours; maximum 100 m Eq per dose. Titrate based on serum chloride and acid-base status.
Not recommended in children <12 years for viral infections due to Reye's syndrome risk (contraindicated).
Start at lower end of adult dosing (e.g., 1.5 g intravenously) due to age-related decreased renal function; monitor electrolytes and renal function closely.
Increased risk of GI bleeding and renal impairment; use lowest effective dose, monitor renal function and signs of bleeding.
None
None
Avoid in patients with impaired renal or hepatic function; may cause hyperammonemia and hepatic coma.,Use with caution in patients with cardiac failure or pulmonary edema due to risk of fluid overload.,Monitor serum chloride, bicarbonate, and p H levels during therapy.
Increased risk of gastrointestinal bleeding and ulceration; Reye syndrome in children with viral illness; Hemorrhagic stroke risk with high doses; Impaired renal function in predisposed patients; Bronchospasm in aspirin-sensitive asthma; Anaphylactic reactions; Use caution in patients with hepatic impairment or G6PD deficiency.
Severe hepatic insufficiency,Severe renal impairment,Hyperammonemia,Uremia,Ammonium toxicity
Known hypersensitivity to NSAIDs or aspirin; Active peptic ulcer disease or GI bleeding; Severe renal impairment (e GFR <30 m L/min); Hemorrhagic diathesis; Children with viral infection (Reye syndrome); Third trimester of pregnancy; Severe hepatic impairment.
No significant food interactions known. However, a diet low in chloride may reduce efficacy. Avoid excessive intake of alkalinizing foods (e.g., citrus fruits, vegetables) that may counteract the acidifying effect.
Avoid alcohol; may increase risk of gastrointestinal bleeding. No specific food restrictions, but taking with food can reduce gastric irritation. Avoid high-dose vitamin C supplements as they may increase salicylate levels.
Ammonium chloride is not known to be teratogenic in humans. No structural anomalies have been reported with first trimester exposure. In second and third trimesters, maternal acidosis from excessive dosing could potentially affect fetal acid-base balance, but no specific fetal risks are documented. Overall, classified as FDA Pregnancy Category C.
First trimester: No well-controlled studies. Avoid use unless clearly needed. Second and third trimesters: Aspirin should be avoided due to risk of premature closure of ductus arteriosus, oligohydramnios, and increased risk of maternal and fetal bleeding. High doses may cause constriction of ductus arteriosus in utero and persistent pulmonary hypertension in newborn.
Excretion into breast milk is unknown. M/P ratio not available. Caution advised due to potential for neonatal acidosis if maternal doses are high. Short-term use is likely compatible with breastfeeding.
Small amounts of aspirin are excreted in breast milk. M/P ratio not established. Use with caution in breastfeeding women; avoid high doses due to risk of Reye's syndrome in infants and potential for adverse effects on platelet function.
No specific dosing adjustments required in pregnancy. However, due to pregnancy-associated hyperventilation and renal changes, monitor acid-base status. Initiate at low doses and titrate based on serum chloride and bicarbonate levels.
Pregnancy increases clearance of aspirin; however, dose adjustments are not routinely recommended due to narrow therapeutic index. Use lowest effective dose for shortest duration. Avoid in third trimester.
Ammonium chloride 2.14% is a systemic acidifying agent used to treat metabolic alkalosis. Monitor serum electrolytes (especially chloride and bicarbonate) and arterial blood gases closely. Avoid in patients with severe hepatic or renal impairment, as ammonium ions can precipitate hepatic encephalopathy or worsen acidosis. Infuse slowly to prevent hemolysis. Use with caution in patients with respiratory acidosis.
8-Hour Bayer is enteric-coated aspirin designed for extended release, reducing gastrointestinal irritation. Onset of action is delayed; not suitable for acute pain or rapid antiplatelet effect. Use with caution in patients with history of peptic ulcer disease or on anticoagulants. Monitor renal function in elderly or dehydrated patients. Avoid in children with viral illness due to Reye's syndrome risk.
This medication is used to treat low acid levels in the blood.,Your healthcare provider will monitor your blood tests regularly while on this medicine.,Report any signs of allergic reaction (rash, itching, swelling) or symptoms of acidosis (confusion, rapid breathing) immediately.,Avoid taking other medications or supplements without consulting your doctor, as they may interfere with this treatment.,Do not stop this medication abruptly without medical advice.
Take with a full glass of water; do not crush or chew the tablet.,Do not use within 7 days before surgery due to bleeding risk.,If used for pain, consult a doctor if symptoms persist for more than 10 days.,Avoid alcohol while taking this medication to reduce stomach bleeding risk.,Seek medical attention for signs of bleeding (black stools, blood in vomit).
"Ammonium chloride, an acidifying agent, reduces urinary pH, which increases the renal clearance of lisdexamfetamine and its active metabolite d-amphetamine. This accelerated elimination leads to decreased systemic exposure and potentially diminished therapeutic efficacy of lisdexamfetamine. Clinically, patients may experience reduced symptom control for ADHD or binge eating disorder, requiring dose adjustments or alternative therapies."
"Sufentanil, a potent opioid analgesic, may increase renal excretion of ammonium chloride by promoting diuresis through opioid-induced release of antidiuretic hormone (ADH) and subsequent water reabsorption, leading to dilutional acidosis and enhanced ammonium excretion. This interaction can result in reduced serum ammonium levels and decreased efficacy of ammonium chloride as an acidifying agent, potentially compromising its therapeutic effect in metabolic alkalosis or urinary tract infections. Clinical outcomes may include incomplete correction of metabolic alkalosis or reduced antimicrobial activity of ammonium chloride in the urine."
"Ammonium chloride acidifies the urine, which increases the renal excretion of amphetamine by favoring its ionized form in the tubular lumen, thereby reducing its reabsorption. This leads to a decreased serum concentration of amphetamine and potentially diminished therapeutic efficacy. Clinically, patients may experience reduced mood-elevating or stimulant effects, requiring dose adjustment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMMONIUM CHLORIDE 2.14% vs 8-HOUR BAYER, answered by our medical review team.
AMMONIUM CHLORIDE 2.14% is a Expectorant/Systemic Acidifier that works by Ammonium chloride is an acidifying agent. It dissociates into ammonium and chloride ions. The ammonium ion is metabolized in the liver to urea and hydrogen ions, leading to metabolic acidosis. This reduces blood p H and increases renal excretion of alkaline urine.. 8-HOUR BAYER is a NSAID that works by Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMMONIUM CHLORIDE 2.14% and 8-HOUR BAYER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMMONIUM CHLORIDE 2.14% is: For metabolic alkalosis: 1.5 to 3 g (approximately 280 to 560 m Eq) intravenously over 4 to 6 hours; adjust based on serum chloride and p H.. The standard adult dose of 8-HOUR BAYER is: 325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMMONIUM CHLORIDE 2.14% and 8-HOUR BAYER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMMONIUM CHLORIDE 2.14% is classified as Category C. Ammonium chloride is not known to be teratogenic in humans. No structural anomalies have been reported with first trimester exposure. In second and third trimesters, maternal acido. 8-HOUR BAYER is classified as Category C. First trimester: No well-controlled studies. Avoid use unless clearly needed. Second and third trimesters: Aspirin should be avoided due to risk of premature closure of ductus arte. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.